Ohno R, Kimura K
Cancer. 1986 Apr 15;57(8 Suppl):1685-8. doi: 10.1002/1097-0142(19860415)57:8+<1685::aid-cncr2820571310>3.0.co;2-0.
A Phase II study of interferon alfa-2a was conducted in 64 patients with multiple myeloma (42 IgG, 16 IgA, 5 Bence-Jones type, and 1 IgD) in a multi-institutional cooperative trial. Partial remission was obtained in 10 (21.3%) of 47 evaluable patients, and minor responses in 5 (10.6%) of 47. Remission was reached at 22 to 89 days (median, 29 days) after the initiation of interferon alfa-2a and lasted 4 to 55 weeks (median, 8 weeks). Side effects were noted in more than two-thirds of patients, and included fever (58%), malaise (20%), anorexia (52%), nausea-vomiting (26%), lethargy (2%), and myelosuppression (56%). They were all reversible on discontinuation of interferon alfa-2a. Antibody to interferon alfa-2a was detected in 1 of 20 patients tested during the course of treatment. Thus, interferon alfa-2a was effective in multiple myeloma, producing unequivocal response in 21.3% of patients without unacceptable side effects.
在一项多机构合作试验中，对64例多发性骨髓瘤患者（42例IgG型、16例IgA型、5例本-周蛋白型和1例IgD型）进行了干扰素α-2a的II期研究。47例可评估患者中有10例（21.3%）获得部分缓解，47例中有5例（10.6%）获得轻微缓解。在开始使用干扰素α-2a后22至89天（中位时间为29天）达到缓解，缓解持续4至55周（中位时间为8周）。超过三分之二的患者出现副作用，包括发热（58%）、不适（20%）、厌食（52%）、恶心呕吐（26%）、嗜睡（2%）和骨髓抑制（56%）。停用干扰素α-2a后这些副作用均可逆转。在治疗过程中检测的20例患者中有1例检测到抗干扰素α-2a抗体。因此，干扰素α-2a对多发性骨髓瘤有效，在21.3%的患者中产生了明确的反应，且无不可接受的副作用。
